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We synthesized a variant, recombinant fibrinogen
modeled after the heterozygous dysfibrinogen Vlissin-
gen/Frankfurt IV, a deletion of two residues, gAsn-319
and gAsp-320, located within the high affinity calcium-
binding pocket. Turbidity studies showed no evidence of
fibrin polymerization, although size exclusion chroma-
tography, transmission electron microscopy, and dy-
namic light scattering studies showed small aggregates.
These aggregates did not resemble normal protofibrils
nor did they clot. Fibrinopeptide A release was normal,
whereas fibrinopeptide B release was delayed approxi-
mately 3-fold. Plasmin cleavage of this fibrinogen was
not changed by the presence of calcium or Gly-Pro-Arg-
Pro, indicating that both the calcium-binding site and
the “a” polymerization site were non-functional. We con-
clude that the loss of normal polymerization was due to
the lack of “A-a” interactions. Moreover, functions asso-
ciated with the C-terminal end of the g chain, such as
platelet aggregation and factor XIII cross-linking, were
also disrupted, suggesting that this deletion of two res-
idues affected the overall structure of the C-terminal
domain of the g chain.
Fibrinogen is a 340-kDa glycoprotein that consists of six
polypeptides chains, (Aa, Bb, and g)2. The molecule is symmet-
ric, consisting of two globular D nodules connected to a central
E nodule by a coiled-coil region (1). The D nodule consists of a
portion of the coiled-coil region and the C termini of both the Bb
and g chains, whereas the E nodule consists of the N termini of
all six polypeptides. Thrombin cleaves the N termini of both the
Aa and the Bb chains, releasing fibrinopeptides A (FpA)1 and B
(FpB) and producing fibrin monomers that polymerize to form
a fibrin clot. FpA is released first, exposing the polymerization
site “A” that binds to the polymerization site “a” in the g chain
in the D domain of another molecule (2). This “A-a” interaction
allows molecules to align into double-stranded, half-staggered
protofibrils (3, 4). It is unclear by what molecular mechanism
FpB release affects polymerization, although a commonly ac-
cepted model proposes that FpB is released from growing pro-
tofibrils, enhancing the assembly of protofibrils into fibers (5–
7). Release of FpB exposes the “B” polymerization site that
binds to the “b” site (2), which may be located in the Bb chain
(8, 9) or the Aa chain (10). In vivo, the result of fibrin polym-
erization is an intricate fibrous network that, along with plate-
lets, forms a hemostatic plug (11).
X-ray crystallography studies have defined several impor-
tant residues of the C-terminal domain of the g chain. When
the peptide Gly-Pro-Arg-Pro (GPRP), which mimics the “A”
site, was co-crystallized with either two covalently linked D
nodules (12) or the g C-terminal fragment of the D nodule (13),
side chains from amino acids Gln-329, Asp-330, and Asp-364
were shown to interact with the peptide, forming the “a” site.
Two of the three high affinity calcium-binding sites in fibrino-
gen (14, 15) are in the individual C termini of the g chains.
These g chain calcium-binding sites lie adjacent to the polym-
erization pocket “a” (12, 13, 16). The specific residues that bind
calcium are Asp-318, Asp-320, Phe-322, and Gly-324 (16). The
structure of the last 14 residues of the C terminus of the g chain
(g398–g411) has been difficult to resolve. Crystallography of a
30-kDa fragment of g chain provided information through res-
idue 401 (16); the last residue resolved in the structure of the
80-kDa fragment D was 398 (12). Nonetheless, biochemical
studies have shown that the sites necessary for factor XIII
(FXIII) g chain cross-linking and platelet aggregation reside in
these C-terminal residues. Specifically, FXIII forms a covalent
bond between gGln-398 on one molecule and gLys-406 from
another molecule (17). The last four residues, g408–411, are
required for platelet aggregation (18).
We have synthesized the recombinant fibrinogen, gD319,320,
modeled after the heterozygous dysfibrinogen Vlissingen/
Frankfurt IV (V/F IV), in which residues gAsn-319 and gAsp-
320 are absent. We found that calcium binding, fibrin polym-
erization, and platelet aggregation were completely disrupted
with the recombinant variant, in contrast to the plasma V/F IV
fibrinogen, where functions were partially impaired (19). These
results suggest that the overall structure of the g C-terminal
fragment has been altered.
EXPERIMENTAL PROCEDURES
Materials—All chemicals were of reagent grade and, unless specified,
were purchased from Sigma. Human a-thrombin was purchased from
Enzyme Research Laboratories, Inc. (South Bend, IN), and recombinant
hirudin was purchased from Calbiochem-Novabiochem Corp. Factor
XIII was a generous gift from Dr. Kevin Siebenlist (Sinai Samaritan
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Medical Center, Milwaukee, WI). Plasminogen was purified from hu-
man plasma by the method previously described (20) and stored at
220 °C. Streptokinase was purchased from American Diagnostica
(Greenwich, CT).
Construction of the Vector and Expression of the Protein—The ex-
pression vector pMLP-g contains the entire g chain cDNA and has been
described (21). The 6 base pairs coding for Asn-319 and Asp-320 were
deleted by oligo-directed mutagenesis using the Transformer TM site-
directed mutagenesis kit from CLONTECH Laboratories (Palo Alto,
CA) based on the procedure described by Deng et al. (22). The primers
used to construct the mutation have been described (23). Chinese ham-
ster ovary cells, which expressed the human Aa and Bb fibrinogen
chains, were co-transfected with the mutant g chain expression vector
and a plasmid containing the selection gene, pMSV his (see Ref. 21 for
details). Individual clones, secreting high amounts of fibrinogen as
determined by enzyme-linked immunosorbent assay, were grown in
serum-free medium in roller bottles for large scale protein expression.
The medium was harvested; phenylmethylsulfonyl fluoride was added,
and the medium was stored at 220 or 270 °C.
Purification of Recombinant Fibrinogen—Both gD319,320 and nor-
mal recombinant fibrinogen (24) were purified by ammonium sulfate
precipitation and immunoaffinity chromatography using IF-1 mono-
clonal antibody (Iatron Corp., Tokyo, Japan) conjugated to Sepharose
4B (see Refs. 24 and 25 for details). Proteins were dialyzed against 20
mM HEPES, pH 7.4, 150 mM NaCl (HEPES buffer), aliquoted, and
stored at 270 °C. To test the purity and assembly of the recombinant
fibrinogen, proteins were analyzed by SDS-PAGE under reduced and
non-reduced conditions by the method of Laemmli (26).
Thrombin-catalyzed Fibrin Polymerization—Polymerization was
monitored at ambient temperature, and the change in turbidity at 350
nm using a Biospec 1601 spectrophotometer (Shimadzu Corp., Tokyo,
Japan) was as described (24). Briefly, in a 100-ml cuvette (Starna Cells,
Inc., Alscadero, CA), 10 ml of thrombin (0.5 units/ml) was added at zero
time to 90 ml of fibrinogen (0.11 mg/ml), in HEPES buffer containing 1
mM CaCl2.
Size Exclusion Chromatography—Reactions were initiated by adding
10 ml of thrombin (4 units/ml) to 90 ml of fibrinogen (0.45 mg/ml). At
specified time points, 1 ml of hirudin (2,000 units/ml) was added to
inhibit thrombin. Samples were immediately injected onto an Amer-
sham Pharmacia Biotech HR 10/30 column packed with Superose 6
resin according to the manufacturer’s instructions; this resin has a
separation range from 5 to 5,000 kDa. The column was equilibrated
with the reaction buffer (HEPES buffer containing 1 mM CaCl2). The
products were eluted under constant flow at 1 ml/min and monitored at
280 nm. The void volume was determined with blue dextran 2,000
(Amersham Pharmacia Biotech).
Plasmin Protection Assay and Western Blot—Fibrinogen (0.1 mg/ml)
was preincubated at ambient temperature for 15 min with EDTA (5
mM), CaCl2 (5 mM), or GPRP (2 mM). Meanwhile, 100 ml of plasminogen
(0.11 mg/ml) was activated with 10 ml of streptokinase (10,000 units/ml)
for 5 min, and 2 ml was added to the fibrinogen samples (100 ml) and
incubated overnight at 37 °C. After incubation, the samples were run on
a 7.5% SDS-PAGE gel, under non-reduced conditions, as described by
Laemmli (26). The gel was electroblotted in 50 mM Tris, 380 mM glycine,
0.1% SDS, 20% methanol at 150 mA for 1.5 h to a nitrocellulose
membrane (Micron Separations Inc, Westborough, MA). The membrane
was blocked overnight at 4 °C in TBS (20 mM Tris-HCl, pH 7.4, 150 mM
NaCl) with 5% non-fat milk. Then it was incubated with a 1:10,000
dilution of rabbit polyclonal antiserum to fibrinogen (Dako, Carpente-
ria, CA) for 2 h in TBST (TBS with 0.05% Tween 20 (Aldrich)), contain-
ing 1% bovine serum albumin. The membrane was next washed three
times with TBST and incubated with a 1:5000 dilution of goat anti-
rabbit IgG conjugated to horseradish peroxidase (Calbiochem) for 1 h in
TBST with 1% bovine serum albumin. The blot was washed three times
and developed with ECLTM Western blotting Detection Reagent (Am-
ersham Pharmacia Biotech).
Thrombin-catalyzed Fibrinopeptide Release—Reactions initiated by
adding thrombin (either 0.01 or 0.005 units/ml) to fibrinogen (0.1 mg/
ml) in HEPES buffer containing 1 mM CaCl2 were performed as de-
scribed (27). Immediately after thrombin addition, the solutions were
aliquoted, and at specified time points, the samples were boiled for 15
min to stop the reaction. The samples were centrifuged for 15 min at
13,000 3 g, and the supernatants were stored at 270 °C. The amount of
FpA and FpB in the supernatants was monitored by reverse phase high
performance liquid chromatography. The FpA and FpB peak areas were
calculated, and the data were fit to two successive first-order rate
equations, and specificity constants, kcat/Km, were calculated as de-
scribed (27). The means were compared by an unpaired t test using
Statview (Abacus Concepts, Berkeley, CA).
Transmission Electron Microscopy—Reactions were initiated by add-
ing 3 ml of thrombin (4 units/ml) to 27 ml of fibrinogen (0.45 mg/ml,
HEPES buffer containing 1 mM CaCl2). At specified time points, 5 ml of
the reaction was added to tubes containing 5 ml of hirudin (4 units/ml).
These samples were immediately diluted in 90 ml of 50 mM ammonium
formate, 70% glycerol, pH 7.4, and sprayed onto freshly cleaved mica.
The samples were dried and rotary-shadowed with tungsten in a Den-
ton Vacuum DV-502, as described previously (28–30). The shadowed
protein films were picked up on 400 mesh copper grids and viewed on a
LEO EM 910 transmission electron microscope.
Isolation of Human Platelets and ADP-induced Aggregation—The
human platelets were isolated by the method previously described (18).
Briefly, human blood was drawn into citrate, and the platelet-rich
plasma was obtained by centrifugation at 800 rpm for 20 min. Prosta-
glandin E-1 (final concentration 20 nM) was added, and the sample was
centrifuged again at 1800 rpm for 20 min. The pellet containing plate-
lets was resuspended in Tyrode’s buffer, pH 7.2 (10 mM HEPES, 135 mM
NaCl, 2.7 mM KCl, 12 mM NaHCO3, 5.5 mM glucose, 2% bovine serum
albumin), and loaded onto a Sepharose CL-2B column. The platelets
were eluted, and CaCl2 was added to 1 mM and MgCl2 added to 2 mM.
For aggregation, 2 3 108 platelets/ml were preincubated at 37 °C with
250 nM fibrinogen, prior to activation with 10 mM ADP. Aggregation of
stirred solutions was monitored with a platelet aggregometer (Chrono-
Log) as the increase in light transmission. Normal and gD319,320
fibrinogens were assayed three times with one platelet donor.
FXIII Fibrin and Fibrinogen Cross-linking and Western Blot—For
fibrin cross-linking, each reaction contained 16 ml of fibrinogen (0.375
mg/ml), 2 ml of FXIII (0.04 mg/ml), and 2 ml of thrombin (3 units/ml) in
HEPES buffer containing 1 mM CaCl2. After incubation at ambient
temperature, the reaction was stopped with the addition of reducing
buffer followed by boiling. For gD319,320 fibrinogen, an additional set
of experiments was performed where 16 ml of fibrinogen (0.375 mg/ml)
was first incubated with 2 ml of thrombin (3 units/ml) for 4 h. Next, 2 ml
of FXIII (40 units/ml) and 1 ml of thrombin (3 units/ml) were added and
incubated for the specified times. For fibrinogen cross-linking, 18 ml of
FXIII (0.67 mg/ml) and 18 ml of thrombin (20 units/ml) were mixed in
the presence of HEPES buffer containing 1 mM CaCl2 and incubated at
37 °C for 35 min to activate the FXIII. Thrombin was inhibited by
incubating with 12 ml of hirudin (450 units/ml) at ambient temperature
for 1 min. Four ml of the FXIIIa mix was added to 16 ml fibrinogen (0.375
mg/ml) and incubated at ambient temperature for the specified times.
All cross-linked products were analyzed on 7.5% reduced gels, electro-
phoresed, and blotted as described for the plasmin protection assay.
Dynamic Light Scattering—The variant gD319,320 fibrinogen was
further purified by gel filtration chromatography with an Amersham
Pharmacia Biotech 10/50 HR column packed with Superose 6B resin.
The elution buffer was HEPES buffer, and the flow rate was 1 ml/min.
Peak fractions were collected, concentrated using a Millipore Ultra-
free® centrifugal filter device (Millipore Corp., Bedford, MA), and used
for polymerization. All fibrinogen solutions were filtered using a 0.2-mm
Millipore filter before use to remove dust. Light-scattering intensity
versus time measurements were performed using a 35-milliwatt He-Ne
laser (model 120, Spectra Physics Inc., Mountain View, CA), a red-
sensitive photomultiplier tube (R298P, Hamatsu, Middlesex, NJ), and a
Brookhaven Instruments BI200 SM goniometer at a 90o angle (31, 32).
For dynamic light scattering, a 72-channel digital correlator (BI-2030
AT, Brookhaven Instruments) was used with a “multiple sample times”
option to divide each channel into four distinct real-time bases, allowing
for an expanded decay time collection range. Data were acquired using
the program BI-30ATN, and the resultant auto-correlation functions
were analyzed employing cumulants analysis to obtain z-average trans-
lational diffusion coefficients (33–35) and the CONTIN algorithm to
obtain size distributions (36). Polymerizations were performed at 0.2
mg/ml fibrinogen, 0.3 units/ml thrombin in HEPES buffer. Time-aver-
aged intensities were taken incrementally for 4 h.
RESULTS
Characterization of the Purified gD319,320 Fibrinogen
The recombinant fibrinogen gD319,320 was synthesized and
purified as described under “Experimental Procedures.” SDS-
PAGE performed under non-reduced conditions demonstrated
that the variant fibrinogen was pure and that it was assembled
into the 340-kDa molecule (data not shown). A reduced gel
showed that all three chains were produced and were intact
(Fig. 1). As previously demonstrated with the plasma fibrino-
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gen V/F IV (19), the variant g chain (lane 2) had a different
mobility than the normal g chain (lane 1). The difference in
mobility was clearly seen in lane 3, with a 1:1 mix of normal
and variant g chain.
“A-a” Interactions Are Missing in gD319,320 Fibrin
Turbidity Studies—Thrombin-catalyzed polymerization was
monitored as turbidity at 350 nm. Under conditions where
normal fibrinogen polymerized rapidly, gD319,320 fibrinogen
did not show a rise in turbidity (Fig. 2). Additional experiments
(data not shown) were performed under varied conditions that
augment polymerization. Nevertheless, no turbidity change
was detected with gD319,320 fibrinogen, even when the throm-
bin concentration was increased to 10 units/ml, the fibrinogen
concentration was increased to 1.3 mg/ml, the temperature was
lowered to 14 °C, the duration of the experiment was extended
to 14 h, or the calcium concentration was raised to 10 mM.
Fibrinopeptide Release—To test whether the polymerization
curves resulted from a blocked “A” site, we measured fibrin-
opeptide A and B release from normal and gD319,320 fibrino-
gen over a 2-h time course. The data were fit to two successive
first-order rate equations under the assumption that FpA was
released before FpB (37). Fig. 3 shows that indeed both FpA
and FpB were released from gD319,320 fibrinogen, but the
release of FpB was delayed relative to normal fibrinogen. The
kinetic data presented in Table I show that FpA was released
at a normal rate, whereas FpB was released at a rate about
3-fold slower than normal. The delayed release of FpB indicates
that protofibril formation was impaired, as the release of FpB
is reported to be accelerated by protofibril formation (5).
GPRP Protection—To determine whether the “a” site was
functional in gD319,320 fibrinogen, we examined plasmin
cleavage in the presence of GPRP, which mimics the “A” site
(38). After incubating gD319,320 or normal fibrinogen with
GPRP, we performed a plasmin digest as described under “Ex-
perimental Procedures.” As shown in Fig. 4, normal fibrinogen
was protected from plasmin cleavage by the presence of GPRP
(lane 3), as the product labeled D1 remained. Normal fibrino-
gen was also protected from cleavage in the presence of 5 mM
CaCl2 (lane 4), as described previously (39). In the absence of
calcium or GPRP (lane 1), plasmin cleavage was demonstrated
by the loss of the D1 product and the appearance of D2 and D3,
as described previously (39, 40). We examined plasmin cleav-
age of gD319,320 fibrinogen under all three conditions and
found no protection from plasmin cleavage as evidenced by the
D2 and D3 products (lanes 6–8). Because the two-residue de-
letion removed part of the high affinity calcium-binding site
(13, 16), it was not surprising that calcium provided no protec-
tion to gD319,320 fibrinogen (lane 8), similar to data obtained
with plasma V/F IV (19). We conclude from the plasmin cleav-
age profile that GPRP did not bind to gD319,320 fibrinogen.
gD319,320 Fibrin Monomers Interact to Form Small Aggre-
gates Size Exclusion Chromatography—We further examined
the polymerization of gD319,320 fibrin by size exclusion chro-
matography to determine whether products larger than fibrin
monomers were formed (Fig. 5). At various time points, throm-
bin was inhibited, and the reaction products were immediately
FIG. 1. Characterization of gD319,320 fibrinogen. SDS-PAGE gel
(10%) was run under reduced conditions and stained with Coomassie
Brilliant Blue (26). Lane 1, normal recombinant fibrinogen; lane 2,
gD319,320 fibrinogen; lane 3, 1:1 mix of normal and gD319,320
fibrinogen.
FIG. 2. Polymerization of normal and gD319,320 fibrin. Repre-
sentative turbidity curves of 0.1 mg/ml fibrin (normal or gD319,320)
polymerized by 0.05 units/ml thrombin in the presence of 1 mM CaCl2
are shown. Solid line, normal fibrin; dashed line, gD319,320 fibrin.
FIG. 3. Fibrinopeptide release of normal and gD319,320 fibrin-
ogen. Representative data for the thrombin-initiated time course of
fibrinopeptide A (F and E) and fibrinopeptide B (3 and f) are shown.
J, I, and solid line represent normal fibrinogen; E, B, and dashed line
represent gD319,320 fibrinogen. Reactions were initiated by adding
0.005 units/ml thrombin to 0.1 mg/ml fibrinogen. The lines represent
the best fit of the data into the equation as described (37).
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run on a size exclusion column.
When thrombin was added to normal fibrinogen, polymeri-
zation was evident almost instantly. A peak at the void volume
was seen as early as 28 s (data not shown), and a small mon-
omer peak was still evident at 1 min (Fig. 5, panel B). After 3
min, a monomer peak was not detected (panel C), and only a
small peak at the void volume was seen. With gD319,320 fi-
brinogen, the result was quite different. At 3 min (panel E),
most of the protein was still in the monomer peak. A peak at
the void volume was not seen until 30 min (data not shown),
and after 240 min (panel F), the monomer peak was still evi-
dent. The void volume peak was not present when gD319,320
fibrinogen was incubated with inhibited thrombin for 240 min
(data not shown), ensuring that the formation of high molecu-
lar components was thrombin-dependent.
Finally, we observed that the size distribution of larger spe-
cies was different between the normal and gD319,320 fibrin.
For example, at 1 min, normal fibrinogen had two distinctive
fractions represented by two peaks with little material between
the two peaks. In contrast, at 240 min, gD319,320 fibrin had
two major peaks, but there was also evidence of a broad spec-
trum of material between these two peaks. We concluded that
gD319,320 fibrin is capable of forming higher molecular weight
species, although the nature of this material could not be de-
termined by size exclusion chromatography.
Transmission Electron Microscopy—To characterize this
high molecular weight material, we used transmission electron
microscopy. We performed reactions as for size exclusion chro-
matography, inhibited thrombin at specific times, and imme-
diately diluted and sprayed the solutions onto mica. The sam-
ples were visualized by rotary shadowing with tungsten (Fig.
6). Under these conditions, normal fibrin became a gel within 1
min, such that at 1 min and thereafter only the unclottable/
soluble fraction of normal fibrin was visible by transmission
electron microscopy, and the microscopic fields were sparsely
populated with molecules (Fig. 6, panel C). We limited our
analysis of normal fibrin to time points #1 min, and we as-
sumed that the discernible fibrin monomers and aggregates
were those that did not incorporate into the clot. In contrast,
under these conditions gD319,320 fibrin did not form a gel, and
over the 4-h incubation, microscopic fields remained densely
populated with molecules (Fig. 6, panel D).
As can be seen in Fig. 6, the gD319,320 fibrinogen molecules
(panel B) appeared the same as normal fibrinogen molecules
(panel A); most gD319,320 fibrinogen molecules appeared tri-
nodular, and the majority of molecules were monomeric, and
there were no obvious abnormal structures. Following incuba-
tion with thrombin, both normal and gD319,320 fibrin demon-
strated a shift in the population of molecules seen. We analyzed
many fields, counted the number of molecules, and scored these
as monomers, pairs, or aggregates (Table II). Paired molecules
were defined as two molecules touching each other in any
orientation, whereas aggregates were defined as a group of
three molecules or more. The data were expressed as a percent-
age of molecules (of total counted) in monomers, pairs, or ag-
gregates, where, for example, the number of molecules counted
as pairs was twice the number of pairs. Aggregates from both
normal and gD319,320 fibrin were scored as being either elon-
gated, indicated by an arrowhead, or irregular-shaped, indi-
cated by an asterisk, in Fig. 6, panels E and F. Often, it was
difficult to discern if a nodule belonged to one molecule or
another, so the number of monomers per aggregate was based
on an estimate of the total number of nodules seen (one mole-
cule is tri-nodular). Consistent with the chromatography data,
after a 4-h incubation, the fraction of gD319,320 fibrin mono-
mers decreased and the fraction of oligomers increased. Al-
though there were no striking differences between normal and
gD319,320 aggregates, analysis of the electron microscopy data
showed that more elongated aggregates were seen with
gD319,320 fibrin than in normal fibrin (Table II). From the
microscopy data, we conclude that after prolonged incubation
gD319,320 fibrin formed aggregates, that these aggregates
were small (on average, four or fewer monomers), and that a
significant fraction of aggregates (about 40% at 4 h) were
elongated as might be expected for early polymerization.
Dynamic Light Scattering—Because both size exclusion
chromatography and transmission electron microscopy only
examined the molecules/aggregates that remained soluble, we
also examined polymerization by dynamic light scattering
which analyzed all products in a closed system. This method
provided time-correlated molecular mass and diffusion coeffi-
cient data, which we compared with corresponding data for
normal fibrinogen (41). Under the conditions of our assay,
within 20 s, analysis of the data with normal fibrin would show
a 6–10-fold increase in molecular mass and a 10-fold drop in
the diffusion coefficient, consistent with formation of elon-
gated, rod-shaped structures, that is, protofibrils (41). When we
examined gD319,320 fibrin by dynamic light scattering (Fig. 7),
the results were significantly different from normal. The mo-
lecular mass increased only 2-fold, on average, and the diffu-
sion coefficient dropped about 1.5-fold after 4 h. These data
were consistent with the formation of small aggregates, con-
sisting on average of 3.9 6 2.5 fibrin monomers per aggregate.
We conclude that the light scattering data and the results seen
by electron microscopy demonstrated that only small aggre-
gates of fibrin were formed.
Distant Functional Sites in Fibrinogen Are Affected by the
gD319,320 Deletion
Fibrin Cross-linking—We also investigated other g chain
coagulation functions, including fibrin cross-linking by the
transglutaminase, FXIII. During polymerization, factor XIII is
activated by thrombin to FXIIIa, which catalyzes the formation
of a covalent bond between Gln and Lys of two g chains (17) or
two or more a chains (42). We examined cross-link formation by
incubating fibrinogen, thrombin, and FXIII, and analyzing the
products on immunoblots from SDS gels run under reducing
conditions. As shown in Fig. 8, with normal fibrinogen, the
formation of g-g dimers was essentially complete after a 5-min
incubation (lane 2). With longer incubation, the g chain com-
pletely disappeared as g-g dimers formed, and the a chain
disappeared, indicating the formation of a-polymers. With
gD319,320 fibrinogen, cross-linking was clearly impaired. After
a 4-h incubation, a faint g-g dimer band was obvious as was a
decrease in both the a and g chains (lane 10). After 24 h (lane
16), the g-g dimer band was still faint, and the g chain band
had faded, but the a chain had completely disappeared. Be-
cause we might expect fibrin cross-linking to be impaired with
monomers that did not polymerize, we also examined cross-
linking after gD319,320 fibrinogen was incubated first with
thrombin for 4 h, followed by addition of FXIII (lanes 11–15).
The immunoblot demonstrated that cross-linking of gD319,320
TABLE I
Specificity constants (Kcat/Km) for fibrinopeptide release
The units are 1026 M21 s21. The average of three experiments is
shown 6 the standard deviation.
Fibrinogen Fibrinopeptide Kcat/Km p value
Normal FpA 12 6 6 1.0
gD319, 320 FpA 12 6 4
Normal FpB 6.8 6 2.3 0.03a
gD319, 320 FpB 2.2 6 0.6
a Represents a significant p value.
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fibrin was somewhat enhanced by prior incubation with throm-
bin, but the rate and extent of cross-link formation was still
markedly impaired.
Fibrinogen Cross-linking—Although polymerizing fibrin is a
better substrate, FXIIIa will also cross-link fibrinogen. In these
experiments, we first activated FXIII and initiated the reaction
by adding FXIIIa to fibrinogen, as described under “Experi-
mental Procedures,” and analyzed the products by Western blot
(Fig. 9). After 1 h, with normal fibrinogen, the blot demon-
strated complete loss of the Aa chain, indicative of a-polymer
formation, and a strong g-g dimer band. After 1 h, with
gD319,320 fibrinogen, there was also complete loss of the Aa
chain, yet the g chain band remained essentially unchanged,
and no band representing g-g dimers was seen. Even after 24 h,
there was no evidence for g-g dimer formation with gD319,320
fibrinogen (data not shown). We conclude that, specifically, the
g chain of gD319,320 fibrinogen was a very poor substrate for
FXIIIa.
Platelet Aggregation—We also examined fibrinogen-medi-
FIG. 4. Plasmin protection assay. A
non-reduced 7.5% SDS-PAGE gel (26)
was immunoblotted with a polyclonal an-
ti-fibrinogen antibody. Normal (lanes
1–4) or gD319,320 (lanes 5–8) fibrinogen
was incubated with plasmin overnight in
the presence of 5 mM EDTA, 5 mM CaCl2,
or 2 mM GPRP. Lanes 1 and 5, undigested
fibrinogen; lanes 2 and 6, EDTA; lanes 3
and 7, GPRP; lanes 4 and 8, CaCl2.
FIG. 5. Size exclusion chromatography. Thrombin was mixed
with fibrinogen and incubated. After the addition of hirudin to inhibit
thrombin, the sample was immediately run over an Amersham Phar-
macia Biotech HR 10/30 column packed with Superose 6B. Panels A–C,
normal fibrinogen after incubation for 0, 1, and 3 min, respectively.
Panels D–F, gD319,320 fibrinogen after incubation for 0 and 3 min and
4 h, respectively. The arrows delineate the void volume.
FIG. 6. Transmission electron microscopy. Thrombin was mixed
with fibrinogen and incubated. After the addition of hirudin used to
inhibit thrombin, the sample was immediately diluted and sprayed on
mica. The mica samples were rotary shadowed with tungsten and
viewed by transmission electron microscopy. Scale bars in all panels
represent 95 nm. Panel A, normal fibrinogen; panel B, gD319,320 fi-
brinogen; panel C, representative field of normal fibrin 1 min after
thrombin addition; panel D, representative field of gD319,320 fibrin 4 h
post-thrombin addition; panel E, elongated (arrowhead) and irregular-
shaped aggregates (asterisk) in normal fibrin, 1 min post-thrombin
addition; panel F, elongated (arrowhead) and irregular-shaped aggre-
gates (asterisk) in gD319,320 fibrin, 4 h post-thrombin addition.
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ated platelet aggregation, the hemostatic function that re-
quires the last four residues (g408–411) of the g chain (18). We
monitored ADP-induced platelet aggregation as a change in
light transmission, as described under “Experimental Proce-
dures,” and the results are shown in Fig. 10. After ADP addi-
tion (indicated by arrows), we saw in both samples the expected
decrease in light transmission that reflects the platelet shape
change indicative of platelet activation. In the presence of
TABLE II
Population of molecules viewed by transmission electron microscopy
The total number of monomers was counted at each time point based on many views. The number of monomers in monomeric, paired, or













Normal, 0 min 524 361 (69%) 104 (20%) 59 (11%) 20
Normal, 28 s 354 142 (40%) 90 (25%) 122 (34%) 9
gD319, 320, 0 min 535 353 (66%) 144 (27%) 38 (7%) 12
gD319, 320, 3 min 485 240 (49%) 162 (33%) 83 (17%) 29
gD319, 320, 2 h 522 200 (38%) 134 (26%) 188 (36%) 47
gD319, 320, 4 h 287 72 (25%) 90 (31%) 125 (43%) 39
a Represents molecules that were touching, in any orientation.
b Represents any group of three molecules or more.
FIG. 7. Dynamic light scattering.
Fractional change in translational diffu-
sion coefficient over time. Thrombin (0.3
units/ml) was added to purified gD
319,320 fibrinogen (0.2 mg/ml) and mon-
itored for 4 h. D/D0, the normalized dif-
fusion coefficient, is shown on one y axis,
and size distributions (units are mono-
mers of fibrin) are shown on the opposite
y axis. Three reactions are shown.
FIG. 8. Fibrin cross-linking with FXIII. Fibrinogen, thrombin, and factor XIII were mixed and incubated for 0, 5, or 20 min or 1 or 4 h. Lanes
1–5, normal fibrinogen; lanes 6–10, gD319,320 fibrin. Lanes 11–15 demonstrate a reaction in which only gD 319,320 fibrinogen and thrombin were
mixed and incubated for 4 h prior to the addition of factor XIII and incubation for 0, 5, or 20 min or 1 or 4 h. Lanes 16 and 17, 24-h time points
for gD319,320 fibrin without and with prior thrombin incubation, respectively. A reduced 7.5% SDS-PAGE gel (26) was immunoblotted with a
polyclonal anti-fibrinogen antibody. The blot was slightly overexposed to enhance the g-g band signal.
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normal fibrinogen, subsequent light transmission increased
rapidly as the platelets aggregated and the solution became
more transparent. In contrast, in the presence of gD319,320
fibrinogen, light transmission did not change after the initial
decrease. We conclude that gD319,320 fibrinogen did not sup-
port normal platelet aggregation.
DISCUSSION
We have synthesized the recombinant gD319,320 fibrinogen,
modeled from the dysfibrinogen V/F IV, which was shown to be
defective in calcium binding, fibrin polymerization, and plate-
let aggregation (19, 43). As with many dysfibrinogens ex-
pressed in heterozygous patients, however, the consequence of
the mutation cannot be fully appreciated in the presence of
normal molecules. Therefore, we synthesized the variant re-
combinant fibrinogen to study the effect of this two-residue
deletion in the absence of normal molecules.
The data presented here suggest that the deletion of residues
319 and 320 affected the structural integrity of the C-terminal
domain of the g chain. Based on the crystallography data, it
was reasonable that a deletion in the calcium binding pocket
would have profound effects on the adjacent polymerization
site, “a” (12, 13, 16). However, it was unexpected that functions
associated with distant residues were also affected. The
FXIIIa-catalyzed formation of g-g dimers was severely im-
paired, with either gD319,320 fibrinogen or fibrin. Because g-g
dimers were not seen with fibrinogen, we concluded that the
loss of function was inherent in the g chain structure per se and
not simply associated with the impaired polymerization of fi-
brin. In addition, ADP-induced, fibrinogen-mediated platelet
aggregation was nonexistent. Previous studies suggest that the
g chain residues needed to support FXIIIa-catalyzed cross-
linking and platelet aggregation are independent from the rest
of the molecule (44–46). For example, a glutathione S-trans-
ferase chimeric protein containing residues g398–411 was able
to bind to GPIIbIIIa, the platelet receptor that mediates fibrin-
ogen-dependent aggregation (46). This chimeric protein was
also a substrate for FXIIIa, forming cross-linked dimers. The
crystal structure of this chimeric protein suggested that this
14-residue segment of the g chain has a flexible, “Z-shaped”
structure, and when this structure was superimposed onto that
from cross-linked fragment D, the residues involved in both
platelet aggregation and FXIII cross-linking were available on
the surface of the domain (46). We conclude, therefore, that in
gD319,320 fibrinogen, these residues are either inaccessible or
in an altered configuration. Perhaps these residues are buried
in the gD319,320 fibrinogen molecule. Irrespective of the exact
nature of the change, the data support the conclusion that the
deletion of residues 319 and 320 altered the structure of these
distant residues. We interpret these data as indicating that the
overall structure of the C-terminal domain of the g chain has
been altered as a result of the two-residue deletion.
The experiments with gD319,320 demonstrated the value of
studies on dysfibrinogens in a homogenous form. Polymeriza-
tion of plasma fibrinogen V/F IV, purified from a heterozygous
individual, was shown to be impaired (19), yet clotting of re-
combinant gD319,320 fibrinogen was undetectable. Impor-
tantly, we have identified a variant fibrinogen in which normal
polymerization does not occur. Previous to these studies, every
variant fibrinogen, whether recombinant or from plasma, has
shown at least minimal polymerization by turbidity studies.
Even fibrin with a substitution at a key residue in “a,” gD364H,
demonstrated a rise in turbidity by 60 min with 0.45 mg/ml
fibrinogen and 0.5 units/ml thrombin (25). We saw no increase
in turbidity under these same conditions.
The results from the size exclusion chromatography, electron
microscopy, and light scattering support the conclusion that
the very first step in polymerization was lost, and normal
protofibrils were not formed. The elongated aggregates appar-
ent with gD319,320 fibrin could be either short protofibrils that
cannot laterally aggregate or aggregates that are coinciden-
FIG. 9. Fibrinogen cross-linking in the absence of thrombin
with activated FXIII. Normal or gD319,320 fibrinogen was incubated
with pre-activated FXIII and the reaction was stopped after 1 h. A
reduced 7.5% SDS-PAGE gel (26) was immunoblotted with a polyclonal
anti-fibrinogen antibody. The blot was slightly overexposed to enhance
the g-g band signal.
FIG. 10. ADP-induced platelet aggregation. 2 3 108 platelets/ml
were preincubated at 37 °C with 250 nM fibrinogen, prior to activation
with 10 mM ADP (indicated by arrows). Aggregation of stirred solutions
was monitored as an increase in light transmission. Thick line, normal
fibrinogen; thin line, gD319,320 fibrinogen.
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tally elongated in shape, similar to protofibrils. We favor the
latter based on their appearance in comparison to previously
published transmission electron microscopy data of normal
protofibrils (47, 48). Because aggregate formation was thrombin-
dependent, interactions that are thrombin-dependent yet
weaker than “A-a” may have a role. One potential interaction
would follow the release of FpB, exposing the “B” site that can
interact with the “b” site. Based on the structure of fragment D
(12), we would expect “B-b” interactions to form unusual poly-
mers, such as the oligomers seen in gD319,320 fibrin. Previous
biochemical studies indicate that an interaction between “A”
and “b” might lead to abnormal polymer forms (49), although
crystallography studies did not detect any “A” binding to “b” (8).
Another thrombin-dependent interaction may occur through
the aC domains, which contact each other and the central E
nodule in fibrinogen (30, 50). In fibrin, the aC domains sepa-
rate from the center of the molecule (30), possibly uncovering
new sites for intermolecular interactions. In transmission elec-
tron microscopy studies, Veklich et al. (30) identified fibrin
aggregates that interact via their aC domains. Similar aggre-
gates were seen on occasion with gD319,320 fibrin (data not
shown), so such interactions may support this abnormal poly-
mer. Regardless of whether “B-b” or “A-b” or aC-aC interac-
tions mediate the formation of gD319,320 fibrin aggregates, the
results provide evidence that without a functional “a”, protofi-
brils, and consequently a fibrin clot, cannot form.
Our polymerization results also support one proposed model
for the structure of b-fibrin, the product of cleavage by a pro-
tease that releases predominantly FpB. This fibrin polymer
only forms at 14 °C (51), but it is normal in that there are
normal protofibrils, fibers, and clots (6, 52). It has been pro-
posed that b-fibrin is mediated through “B-a” interactions (8).
As no turbidity changes were detected when gD319,320 fibrin-
ogen was mixed with thrombin at 14 °C (data not shown), our
data are consistent with this model of b-fibrin that requires a
functional “a” site.
In summary, we have synthesized a recombinant fibrinogen
modeled after the dysfibrinogen V/F IV, a deletion of residues
g319 and g320. The loss or impairment of several coagulation
functions associated with the g chain suggests that a signifi-
cant change in structure has occurred in the molecule. None-
theless, the deletion had no apparent effect on assembly or
secretion, and transmission electron microscopy showed that
the overall tri-nodular structure of the molecule was normal.
Thus, we hypothesize that the deletion has induced a signifi-
cant structural change only within the C-terminal domain of
the g chain.
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